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ABSTRACT
Objective: To identify, critically appraise and
summarise existing systematic reviews on the impact
of global cardiovascular risk assessment in the primary
prevention of cardiovascular disease (CVD) in adults.
Design: Systematic review of systematic reviews
published between January 2005 and October 2016 in
The Cochrane Library, EMBASE, MEDLINE or CINAHL
databases, and post hoc analysis of primary trials.
Participants, interventions, outcomes: Systematic
reviews of interventions involving global cardiovascular
risk assessment relative to no formal risk assessment
in adults with no history of CVD. The primary
outcomes of interest were CVD-related morbidity and
mortality and all-cause mortality; secondary outcomes
were systolic blood pressure (SBP), cholesterol and
smoking.
Results: We identified six systematic reviews of
variable but generally of low quality (mean Assessing
the Methodological Quality of Systematic Reviews 4.2/
11, range 0/11 to 7/11). No studies identified by the
systematic reviews reported CVD-related morbidity or
mortality or all-cause mortality. Meta-analysis of
reported randomised controlled trials (RCTs) showed
small reductions in SBP (mean difference (MD)
−2.22 mm Hg (95% CI −3.49 to −0.95); I2=66%; n=9;
GRADE: very low), total cholesterol (MD −0.11 mmol/L
(95% CI −0.20 to −0.02); I2=72%; n=5; GRADE: very
low), low-density lipoprotein cholesterol (MD
−0.15 mmol/L (95% CI −0.26 to −0.05), I2=47%;
n=4; GRADE: very low) and smoking cessation (RR
1.62 (95% CI 1.08 to 2.43); I2=17%; n=7; GRADE:
low). The median follow-up time of reported RCTs was
12 months (range 2–36 months).
Conclusions: The quality of existing systematic
reviews was generally poor and there is currently no
evidence reported in these reviews that the prospective
use of global cardiovascular risk assessment translates
to reductions in CVD morbidity or mortality. There are
reductions in SBP, cholesterol and smoking but they
may not be clinically significant given their small effect
size and short duration. Resources need to be directed
to conduct high-quality systematic reviews focusing on
hard patient outcomes, and likely further primary
RCTs.
Trial registration number: CRD42015019821.
INTRODUCTION
Cardiovascular disease (CVD) is the leading
cause of death worldwide.1 Contrary to
popular belief, death and disability from
CVD is also a major burden in low-resource
settings2 3 and despite impressive global
reductions in mortality over the last two
decades, years-of-life-lost due to CVD is rising
in low-income and middle-income coun-
tries.4 Prevention is therefore a worldwide
priority.
Global CVD risk assessment (also referred
to as absolute risk assessment, total risk assessment
or risk scoring) is an integrated approach to
prevention that recognises the hazards of
multiple risk factors to determine the abso-
lute risk of experiencing a CVD event in a
given time period. Almost all CVD guidelines
recommend some form of risk scoring as a
Strengths and limitations of this study
▪ This systematic review summarises evidence
from six systematic reviews on the use of global
cardiovascular disease (CVD) risk assessment
for the primary prevention of CVD in adults and
reports important patient outcomes.
▪ The quality of the systematic reviews was
assessed using Assessing the Methodological
Quality of Systematic Reviews and was generally
poor, with inconsistencies in methods, out-
comes, quality appraisal and reporting.
▪ Owing to the deficiencies in the reviews, we
undertook post meta-analyses, which included
further analysis of the identified primary studies
within the reviews and quality appraisal using
GRADE.
▪ Our systematic review was strengthened by its
broad inclusion criteria, which reduced the
chance we missed relevant systematic reviews.
▪ The findings of our post hoc meta-analyses
should be interpreted with caution given the
paucity of evidence and low to very low GRADE
scores.
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way to prioritise and plan primary prevention interven-
tions.5–7 This practice is entrenched in most high-
income countries,5 6 8 and endorsed by the WHO for
low-income and middle-income countries.7
Even with an abundance of clinical guidance and
effective interventions targeting modiﬁable risk factors,
the majority of patients at risk do not achieve sufﬁcient
risk factor control.9–14 In jurisdictions where risk scoring
is part of routine clinical practice, this may be due to
implementation challenges, such as physician attitudes
to and understanding of CVD risk assessment,14–16 chal-
lenges communicating risk to patients and patients’
understanding of risk17 18 or lack of a true effect.
Although calibration and discrimination studies of prog-
nostic risk score models are important, trials on the pro-
spective use of risk scores in practice are required to
determine their impact on patient outcomes.
While the development of global cardiovascular risk
assessment has been the focus of much research,19–22
there is little certainty about its effectiveness in the pre-
vention of CVD. We conducted a systematic review of sys-
tematic reviews to identify, critically appraise and
summarise evidence on the impact of global cardiovas-
cular risk assessment in the primary prevention of CVD.
We chose to conduct a systematic review of systematic
reviews because they can be used to synthesise evidence
for a given intervention on a diversity of outcomes, in
addition to identifying limitations in the methodology
and quality of existing systematic reviews.23
METHODS
We prospectively registered our protocol on PROSPERO
(registration CRD42015019821),24 and deviations from
this plan, which were minor, are described in online
supplementary S1 appendix 1.
Search strategy
We searched the Cochrane Library, EMBASE, MEDLINE
and CINAHL databases from January 2005 to October
2016 (see online supplementary S2 appendix 2 for
detailed search strategies). We searched from 2005
because we felt that more recent systematic reviews were
likely to capture the same primary studies as older sys-
tematic reviews. No language restrictions were applied.
Search strategies used a mix of Medical Subject Heading
(MeSH) terms and keywords and were developed with
an information specialist. We supplemented this strategy
by handsearching the bibliographies of included reviews,
forward citation searching on Google Scholar and Web
of Science and by contacting experts.
Inclusion criteria
We included systematic reviews of studies of any design
that included adults (18 years of age or older) with no
history of CVD (including atrial ﬁbrillation). Reviews
were eligible for inclusion if they considered interven-
tions involving global CVD risk assessment relative to no
risk assessment, irrespective of who performed the risk
assessment, how it was performed and to whom the
information was directed. We excluded studies of peri-
operative CVD risk scores, analogue patients, patients
with existing CVD, validation studies and accuracy
studies of CVD risk scores.
The primary outcomes of interest were CVD-related
morbidity or mortality and all-cause mortality. We sec-
ondarily considered systolic blood pressure (SBP), chol-
esterol and smoking, because together these cause the
majority of premature CVD and have effective interven-
tions to treat them.25 26
Study selection, data extraction and quality assessment
Study selection, data extraction and quality assessment
was done in two phases. We ﬁrst screened systematic
reviews for inclusion, and then screened primary studies
reported in the systematic reviews as required.
Two reviewers screened titles and abstracts for full text
review and disagreement was resolved by consensus. We
screened full text articles for inclusion using the same
method. Two reviewers independently extracted salient
characteristics about the included reviews and their
description of included studies, including the classiﬁca-
tion of interventions as either directed toward the
patient, provider or the patient and provider. The same
reviewers independently assessed methodological quality
using the Assessing the Methodological Quality of
Systematic Reviews (AMSTAR) checklist.27 We documen-
ted the method of quality assessment and extracted the
quality of primary studies as reported by the review
authors. If a primary study was reported by more than
one review, we extracted the quality score from the
review with the highest AMSTAR rating.
We did not initially plan to extract data from primary
studies; however, to address poor or insufﬁcient reporting,
or to verify intervention classiﬁcations, the second phase
involved the same two reviewers extracting additional data
from the primary studies as needed. We extracted data
from primary studies as reported in systematic reviews
and tabulated all results by outcome using Microsoft
Excel 2010 and Microsoft Word 2010. In the event of a
discrepancy, we used the data reported in the primary
study rather than the systematic review. When outcomes
were reported at multiple time points in a single study, we
selected the longest follow-up time with complete data.
Data synthesis
We narratively reported systematic reviews and tabulated
their salient characteristics, including review, author con-
clusions and AMSTAR ratings. For our post hoc analysis
of primary studies reported by systematic reviews, we used
RevMan V.5.3 to construct forest plots and inverse
variance-weighted random effects meta-analyses.28 One
author entered data into RevMan and these were inde-
pendently veriﬁed by a second author. We only included
randomised studies in meta-analyses; other study designs
or randomised studies with insufﬁcient data to
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meta-analyse were reported narratively. For continuous out-
comes, we calculated mean differences and for dichotom-
ous outcomes, risk ratios. We performed subgroup analyses
by the intended target of the intervention (patient, pro-
vider or both). We imputed standard error (SE) when rea-
sonable, using the average SE of studies reporting the
same outcome and in the same subgroup, and in such
cases a sensitivity analysis was performed. For each
outcome meta-analysed, we used the GRADE methodology
to rate the quality of evidence using GRADEpro GDT soft-
ware.29 30 This was done by one author and checked by a
second; disagreements were resolved by consensus. We
used I2 values to estimate statistical heterogeneity.
RESULTS
We screened 6877 studies for inclusion, 6727 of which
were excluded as irrelevant based on title and abstract
(ﬁgure 1). Following full-text review of 150 studies, six
systematic reviews met the inclusion criteria. We
excluded 144 articles, the majority (n=110) due to the
study design. The six included systematic reviews
together reported 122 unique primary studies, 16 of
which were relevant based on our inclusion criteria,
including adults with no history of CVD and global CVD
risk assessment as an intervention relative to no risk
assessment. Of these, none reported CVD-related mor-
bidity or mortality or all-cause mortality, 12 reported
Figure 1 Flow diagram of
included systematic reviews,
primary studies and the outcomes
reported.
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SBP, 10 reported cholesterol and 9 reported smoking
cessation (ﬁgure 1).
Summary of included systematic reviews
Characteristics of included systematic reviews are sum-
marised in table 1. Reviews were generally broad in
scope, published from 2006 to 2015, considered all study
designs and collectively searched 11 databases. AMSTAR
ratings ranged from 0/11 to 7/11 (mean 4.2/11); we
did not exclude any reviews based on quality (see online
supplementary S3 appendix 3). The conclusions of
reviews were consistently of general uncertainty about
the impact of cardiovascular risk assessment on hard
patient outcomes.
Brindle et al31 (AMSTAR 4/11) sought to determine
the accuracy and impact of CVD risk assessment. To
assess impact, they considered randomised controlled
trials (RCTs) of healthcare professionals using a CVD
risk score to aid in primary prevention, relative to usual
care, in populations predominantly free from symptom-
atic CVD (table 1). Although the authors identiﬁed 31
primary studies, the majority of the studies assessed the
accuracy of CVD risk assessment and therefore were
beyond the scope of our review. The authors concluded
that there was little evidence to support the use of risk
scores for primary prevention.
Sheridan and Crespo32 (AMSTAR 4/11) conducted a
much more focused review, speciﬁcally aimed to assess the
beneﬁts and harms of physician knowledge of a global
CVD risk score, relative to no formal risk assessment, in
adults with no history of CVD. Although the authors only
searched MEDLINE, they identiﬁed 11 primary studies,
most of which were relevant to our review (table 1), and
reached similar conclusions as Brindle 2006: ‘surprisingly
little evidence that physician knowledge of global CHD
risk translates into improved clinical outcomes’.32
Sheridan et al33 (AMSTAR 7/11) was distinct from
Sheridan 2008 in that eligible interventions were tar-
geted at patients rather than physicians. To be eligible,
studies (of any design) had to be interventions of global
CVD risk information, solely or as part of a complex
intervention, directed at adults with no history of CVD
to determine the impact of patient-targeted risk infor-
mation on patient outcomes (table 1). In this review,
Sheridan et al searched multiple databases and identi-
ﬁed 18 primary studies; most were relevant to our
review. They concluded that the effect of risk informa-
tion on patients may improve proximal outcomes, such
as accuracy or risk perception, in those who are high
risk but the effect on distal outcomes was not clear.
Waldron et al34 (AMSTAR 5/11) reviewed studies of any
quantitative design that used communication interven-
tions for individualised cardiovascular risk and compared
them to a control or usual care and assessed their impact
on patient-related outcomes (table 1). Although the
authors performed a comprehensive search, only three
of the 15 primary studies identiﬁed were in actual
patients—the rest were of analogue patients and
therefore were not relevant to our review. The authors
were unable to draw strong conclusions citing the need
for better quality trials.
Van Dieren et al35 (AMSTAR 0/11) conducted a
two-part review; the ﬁrst part sought to identify risk
scores that had been developed or validated for people
with type two diabetes, and the second part sought to
ﬁnd studies aimed at assessing the impact on patient
outcomes when these scores were implemented in prac-
tice (table 1). The authors therefore only searched for
impact studies on the risk scores that had been identi-
ﬁed in the former half of their review. Although the
authors identiﬁed 45 primary studies, only three studies
were identiﬁed from the latter half of the review and
were relevant to our review. They concluded that ‘the
impact of applying these risk scores in clinical practice is
almost completely unknown’.35
Usher-Smith et al36 (AMSTAR 5/11) conducted the
most recent and most comprehensive review, although
the searches were conducted in 2013. The authors con-
sidered randomised or non-randomised studies of inter-
ventions consisting of the provision of a CVD risk
estimate to patients, or their providers, in patients with
no history of CVD (table 1). Searching MEDLINE and
PubMED, they identiﬁed 17 primary studies, the vast
majority of which had previously been reported by one
of the aforementioned systematic reviews. However, this
review was the ﬁrst and only review to conduct
meta-analyses, which helped draw stronger conclusions
about impact. The authors concluded that global risk
assessment could improve prescribing and perceived
risk, but not smoking, and their meta-analyses showed
no signiﬁcant effect on SBP or pooled total cholesterol
and low-density lipoprotein (LDL) cholesterol.
Effects of interventions
As the included reviews were of variable, but generally
low quality and only one attempted meta-analysis, we
conducted a post hoc analysis of the primary studies
reported by included systematic reviews that met our
inclusion criteria to gain further insight from the
reported data. Furthermore, some of the reviews insufﬁ-
ciently described included primary studies. Therefore, in
addition to meta-analysis, we tabulated the character-
istics of included primary studies, including quality
ratings for each study as reported by review authors,
which are included in online S4 supplementary
appendix 4. The median follow-up of all included
primary studies reported by reviews was 12 months, but
ranged from 2 to 36 months (see online supplementary
S4 appendix 4). Most interventions used Framingham or
a Framingham-derived risk score; these interventions
and their controls are summarised in detail in online
supplementary S4 appendix 4. None of the systematic
reviews used GRADE to evaluate the quality of studies,
and we therefore included GRADE tables for each
outcome and subgroup in online supplementary S5
appendix 5.
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Table 1 Characteristics of included systematic reviews
Systematic review ID
Brindle 200631 Sheridan 200832 Sheridan 201033 Waldron 201134 van Dieren 201235 Usher-Smith 201536
Review
objective(s)
‘To determine the
accuracy of assessing
CVD risk in the primary
prevention of CVD and
its impact on clinical
outcomes’
‘To assess whether
global CHD risk
scores result in
clinical benefits or
harms’
‘To assess the effect of
providing global CHD
risk information to
adults’
‘To compare different
interventions used to
communicate
cardiovascular risk and
assess their impact on
patient related
outcomes’
‘To review the primary
prevention studies that
focused on the
development,
validation and impact
assessment of a
cardiovascular risk
model, scores or rules’
‘To systematically review
whether the provision of
information on
cardiovascular disease
(CVD) risk to healthcare
professionals and patients
impacts their
decision-making,
behaviour and ultimately
patient health.’
Population People ‘predominantly
free from symptomatic
CVD’
‘Adults (>18) with
no prior history of
CVD’
‘Adults with no history
of CVD’
Adults (>18) ‘People with type 2
diabetes’
People ‘with no history of
CVD’
Intervention(s) ‘Healthcare professional
using a CVD risk score
to aid primary
prevention’
‘Physician
knowledge of a
global CHD risk
score’
‘Global CHD risk
presentation as the
primary intervention or
part of a multipart
intervention’
‘Communication
interventions (of any
format) for
individualised CVD
assessment’
‘CVD predictions
models that have been
developed… or
validated in a diabetes
population’
‘Intervention strategy
consisted of provision of a
CVD risk model estimate
to either physicians or
patients’
Comparison(s) Usual care ‘Either simple risk
factor counting or
no formal
assessment of risk’
Not prespecified Control or usual care
arm
Not prespecified No ‘provision of a CVD
risk model estimate’
Country of
primary
review author
UK United States of
America
United States of
America
UK The Netherlands UK
AMSTAR 4/11 4/11 7/11 5/11 0/11 5/11
Eligible study
designs
RCTs Any design Any design ‘Any quantitative
design’
Not specified Randomised and
non-randomised primary
studies
Databases
searched
CENTRAL, MEDLINE,
EMBASE, CINAHL,
PsycINFO, ZETOC,
ISI Proceedings
MEDLINE MEDLINE, PsycINFO,
CINAHL, Cochrane
Database
ASSIA, CINAHL,
EMBASE, MEDLINE,
PsycINFO, Science
Citation Index
expanded
MEDLINE MEDLINE, PubMed
Date of
database
search
2004 2007 2008 2008 2011 2013
Meta-analysis? No No No No No Yes
Review method
of quality
assessment
No formal assessment.
‘Information on the
methodological quality
Criteria adapted
from the US
Preventive
Criteria adapted from
the US Preventive
Services Task Force
Downs and Black
checklist
Quality not assessed Followed critical appraisal
skills programme
guidelines
Continued
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Table 1 Continued
Systematic review ID
Brindle 200631 Sheridan 200832 Sheridan 201033 Waldron 201134 van Dieren 201235 Usher-Smith 201536
of the trials including the
method of
randomisation,
concealment of
allocation, baseline
group comparisons and
blind outcome
assessment was
collected’
Services Task
Force
Review authors’
conclusions
‘Evidence supporting
the use of
cardiovascular risk
scores for primary
prevention is scarce’
‘We found
surprisingly little
evidence that
physician
knowledge of
global CHD risk
currently translates
into improved
clinical outcomes’
‘Global CHD risk
information seems to
improve the accuracy of
risk perception and may
increase intent to
initiate CHD prevention
among individuals at
moderate to high risk.
The effect of global risk
presentation on more
distal outcomes is less
clear and seems to be
related to the intensity
of accompanying
interventions.’
‘Better quality trials are
needed that compare
different risk
presentation formats
before conclusions can
be drawn’
‘The impact of
applying these risk
scores in clinical
practice is almost
completely unknown,
but their use is
recommended in
various national
guidelines.’
‘There seems evidence
that providing CVD risk
model estimates to
professionals and patients
improves perceived CVD
risk and medical
prescribing, with little
evidence of harm on
psychological well- being.’
CHD, coronary heart disease.
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Primary outcomes
Mortality
No reviews included studies reporting CVD-related or
all-cause mortality (table 2).
CVD morbidity
No reviews included studies reporting CVD-morbidity
(table 2).
Secondary outcomes
Systolic blood pressure
Five reviews reported a total of 12 unique primary
studies (n=23 346) (see online supplementary S4
appendix 4). Of the 12 primary studies, 3 were cluster
RCTs, 8 were RCTs and 1 was an observational
follow-up of an RCT. Nine of the controlled trials
(n=7537) were reported with sufﬁcient data to
meta-analyse, resulting in a mean difference of mean
change of SBP of −2.22 mm Hg (95% CI −3.49 to
−0.95; I2=66%; GRADE: very low) (ﬁgure 2; table 2).
Subgroup analyses by studies of interventions targeting
the patient (n=3), provider (n=3) or both (n=3),
resulted in mean differences of −4.88 mm Hg (95% CI
−8.57 to −1.19; I2=0%; GRADE: very low),
−1.14 mm Hg (95% CI −2.09 to −0.19; I2=46%;
GRADE: low) and −2.77 mm Hg (95% CI −5.91 to
0.37; I2=76%; GRADE: very low), respectively, in the
intervention group relative to control (ﬁgure 2; table
2). We imputed the SE of Lovibond (1986); excluding
this study from the meta-analysis did not signiﬁcantly
change the results of the subgroup analysis or overall
estimate: −4.82 mm Hg (95% CI −9.36 to −0.27;
I2=0%) and −2.12 mm Hg (95% CI −3.41 to −0.83;
I2=68%), respectively.
Two additional patient-directed studies were identi-
ﬁed. The ﬁrst, an RCT,37 evaluated the impact of
health checks which comprised a Framingham-derived
risk score and counselling about risk, relative to usual
care, in middle-aged adults. The study found a differ-
ence in SBP of −2.5 mm Hg (95% CI −3.7 to −1.3)
between the intervention and control group after
3 years; however, this was not adjusted to baseline
values.33 The second, an observational follow-up of an
RCT,38 found no signiﬁcant difference between patients
who received their risk score along with a decision ana-
lysis tool, relative to usual care, after 3 years: adjusted
difference of SBP between intervention and control at
follow-up was 0.94 mm Hg (95% CI −3.2 to 5.1, p value
0.65).
Finally, one RCT, targeting patients and providers,
trained nurses on risk factor measurement and coun-
selling, and provided patients with a CVD risk score
and two to six sessions of counselling.39 Compared
with usual care after 1 year, unadjusted differences in
SBP between intervention and control were
−7.3 mm Hg (p value not reported) and −6.2 mm Hg
(p value not reported), in men and women,
respectively.33
Cholesterol
Six reviews reported a total of nine RCTs and one
cluster RCT (see online supplementary S4 appendix 4).
We considered total cholesterol and LDL cholesterol,
and analysed them separately.
Total cholesterol
Of the seven trials (n=23 406) reporting total choles-
terol, ﬁve (n=7813) were reported with sufﬁcient data to
meta-analyse, resulting in a mean difference of
−0.11 mmol/L (95% CI −0.20, −0.02; I2=72%; GRADE:
very low) (ﬁgure 3; table 2). Subgroup analyses by
studies of interventions targeting the patient (n=2), pro-
vider (n=1) or both (n=2), resulted in mean differences
of −0.07 mmol/L (95% CI −0.13,−0.02; I2=0%; GRADE:
very low), −0.01 mmol/L (95% CI −0.08 to 0.06;
GRADE: very low) and −0.26 mmol/L (95% CI −0.38 to
−0.15; I2=0%; GRADE: very low) (ﬁgure 3; table 2).
Two additional RCTs were reported, one targeting
patients and one targeting patients and providers. The
former,37 evaluated the impact of health checks which
comprised a Framingham-derived risk score and coun-
selling about risk, relative to usual care, in middle-aged
adults. The study found a difference in total cholesterol
of −0.18 mmol/L (95% CI −0.26 to −0.12) between the
intervention and control group after 3 years; however
this was not adjusted to baseline values.33
The latter,39 targeting patients and providers, trained
nurses on risk factor measurement and counselling, and
provided patients with a CVD risk score and two to six
sessions of counselling.39 Compared with usual care
after 1 year, unadjusted differences in total cholesterol
between intervention and control were −0.13 mmol/L
(p value not reported) and –0.09 mmol/L (p value not
reported), in men and women, respectively.33
LDL cholesterol
Five trials (n=4940) reported data on LDL cholesterol,
four of which (n=4505) when meta-analysed yielded a
greater reduction in LDL cholesterol in the intervention
group compared with the control group: mean difference
of −0.15 mmol/L (95% CI −0.26 to −0.05, I2=47%;
GRADE: very low) (ﬁgure 4; table 2). Subgroup analyses
by studies of interventions targeting the patient (n=3) and
the patient and provider (n=1), resulted in mean differ-
ences of −0.15 mmol/L (95% CI −0.27 to −0.03; I2=58%;
GRADE: very low) and −0.23 mmol/L (95% CI −0.47 to
0.01; GRADE: very low), respectively (ﬁgure 4; table 2).
One additional RCT targeting patients assessed the
impact of mailing personalised CVD risk assessment and
encouraging discussion with their primary care physician
to usual care.40 The primary outcome was the occur-
rence of an LDL cholesterol measurement of at least
0.78 mmol/L (30 mg/dL) lower than the baseline meas-
urement during a 9-month follow-up. The trial showed
no signiﬁcant difference between intervention and
control, intention-to-treat analysis resulted in an OR of
0.99 (95% CI 0.56 to 1.74, p=0.96).40
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Table 2 Meta-analysis of the impact of global cardiovascular risk assessment on cardiovascular disease morbidity, mortality, systolic blood pressure, total cholesterol,
low-density lipoprotein cholesterol and smoking cessation
Outcome Patient directed Provider directed
Patient and provider
directed
Overall effect
estimate
CVD morbidity Effect estimate − − − −
I2 (%) − − − −
Quality (GRADE) − − − −
Mortality (CVD-related or
all-cause)
Effect estimate − − − −
I2 (%) − − − −
Quality (GRADE) − − − −
Systolic blood pressure (mm Hg) Effect estimate (MD) (95% CI) −4.88 (−8.57 to −1.19) −1.14 (−2.09 to −0.19) −2.77 (−5.91 to 0.37) −2.22 (−3.49 to −0.95)
I2 (%) 0 46 76 66
Quality (GRADE) very low (●○○○) low (●●○○) very low (●○○○) very low (●○○○)
Total cholesterol (mmol/L) Effect estimate (MD) (95% CI) −0.07 (−0.13 to −0.02) −0.01 (−0.08 to 0.06) −0.26 (−0.38 to −0.15) −0.11 (−0.20 to −0.02)
I2 (%) 0 single study 0 72
Quality (GRADE) very low (●○○○) very low (●○○○) very low (●○○○) very low (●○○○)
LDL cholesterol (mmol/L) Effect estimate (MD) (95% CI) −0.15 (−0.27 to −0.03) − −0.23 (−0.47 to 0.01) −0.15 (−0.26 to −0.05)
I2 (%) 58 − single study 47
Quality (GRADE) very low (●○○○) − very low (●○○○) very low (●○○○)
Smoking cessation (risk of
quitting)
Effect estimate (RR) (95% CI) 1.53 (1.07 to 2.19) 1.90 (0.43 to 8.29) 0.30 (0.01 to 7.07) 1.62 (1.08 to 2.43)
I2 (%) 0 57 single study 17
Quality (GRADE) low (●●○○) very low (●○○○) moderate (●●●○) low (●●○○)
Subgroup analyses were performed by interventions targeting the patient, the provider or both.
LDL, low-density lipoprotein; MD, mean difference, the difference of the mean differences from baseline to follow-up of the intervention arm compared with the control arm; RR, risk ratio.
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Smoking
Three reviews reported a total of eight RCTs and one
cluster RCT and (n=19 873) (see online supplementary
S4 appendix 4). Seven of these trials (n=4131) were
reported with sufﬁcient data to meta-analyse, resulting
in a risk ratio for quitting smoking of 1.62 (95% CI 1.08
to 2.43; I2=17%; GRADE: low) (ﬁgure 5; table 2).
Subgroup analyses by studies of interventions targeting
the patient (n=4), provider (n=2) or patient and
provider (n=1) resulted in risk ratios of 1.53 (95% CI
1.07 to 2.19; I2=0%; GRADE: low), 1.90 (95% CI 0.43 to
8.29; I2=57%; GRADE: very low) and 0.30 (95% CI 0.01
to 7.07; GRADE: moderate), respectively (ﬁgure 5; table
2).
Two additional RCTs were reported by included
reviews, one targeted patients and one targeted patients
and providers. Of the former, one RCT targeting
patients assessed the impact of mailing personalised
Figure 2 Forest plot and meta-analysis of the mean difference of mean change in systolic blood pressure (mm Hg) from
baseline to follow-up between intervention and control groups.
Figure 3 Forest plot and meta-analysis of the mean difference of mean change in total cholesterol (mmol/L) from baseline to
follow-up between intervention and control group.
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CVD risk assessment and encouraging discussion with
their primary care physician to usual care.40 As a second-
ary outcome, the trial sought to record the number of
smokers who quit after nine months, but failed to
provide the actual data stating, ‘non-smoking (among
smokers) was rare and did not vary by group’.40
The other, an RCT targeting patients and providers,
trained nurses on risk factor measurement and counsel-
ling, and provided patients with a CVD risk score and
two to six sessions of counselling.39 Compared with
usual care after one year, unadjusted differences in
smoking prevalence between intervention and control
were −4.1% (p value not reported) and −2.9% (p value
not reported), in men and women, respectively.33
DISCUSSION
To the best of our knowledge, this is the ﬁrst systematic
review of systematic reviews on the impact of global car-
diovascular risk assessment in the primary prevention of
CVD. Reviews on this topic vary in the databases
searched, search strategies used and the speciﬁc popula-
tions and interventions of interest, and their quality was
generally poor (mean AMSTAR 4.2/11, range 0/11 to
7/11). However, they have consistently reported uncer-
tainty about the effectiveness of global CVD risk assess-
ment. Our results show that to date, no reviews or their
included primary studies have reported CVD-related
morbidity or mortality or all-cause mortality. Post hoc
analysis of data reported by included reviews illustrated
Figure 4 Forest plot and meta-analysis of the mean difference of mean change in LDL cholesterol (mmol/L) from baseline to
follow-up between intervention and control group. LDL, low-density lipoprotein.
Figure 5 Forest plot and meta-analysis of the risk ratio of quitting smoking from baseline to follow-up between intervention and
control group.
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very low-quality evidence for small reductions in SBP,
total cholesterol, LDL cholesterol and low-quality evi-
dence for small increases in smoking cessation.
We conducted a post hoc analysis of data reported by
included systematic reviews to compensate for the poor
evidence synthesis of some of the included reviews and
to reduce research waste. Several of the included reviews
highlighted a need for better quality trials on this topic,
and our quality appraisal using GRADE corroborates
these conclusions. Our post hoc analysis illustrated that
all effect estimates were of low GRADE or very low
GRADE quality. Our meta-analyses of data reported by
systematic reviews, although not the primary aim of our
systematic review, advances our knowledge on the
impact of total cardiovascular risk assessment beyond
what was reported by individual systematic reviews. Given
the disparate and poor quality of data reporting and
quality appraisal of the included systematic reviews, we
felt it was responsible to perform better quality evidence
synthesis and quality appraisal.
Our meta-analysis of SBP added ﬁve additional RCTs
compared with the previously reported meta-analysis36
and revealed for the ﬁrst time a statistically signiﬁcant
small reduction in SBP. We also report for the ﬁrst time
statistically signiﬁcant, but small, reductions in total chol-
esterol, LDL cholesterol and smoking. These results
might be explained by improvements in the prescription
of cholesterol-lowering and blood pressure-lowering
treatment,36 and increasing accuracy of patient risk
perception.33 36
Reductions in SBP, LDL cholesterol and smoking
tended to be greatest when cardiovascular risk informa-
tion was directed at patients. The delineation between
patient-directed and provider-directed interventions is
not well resolved, since patients may discuss risk infor-
mation with their provider and vice versa. This phenom-
enon may contaminate the subgroup analysis. A
previous review33 concluded that greater effects were
seen in patients with increased baseline CVD risk; adjust-
ing for baseline CVD risk in our analyses did not explain
the observed trend toward patient-directed
interventions.
Observed reductions in blood pressure, cholesterol
and smoking could lead to reductions in overall risk and
eventual reduction in CVD events. For this to be true,
such changes must be sustained long term to have a
meaningful impact on event rates in individual patients.
However, the median follow-up of all eligible studies
reported by included systematic reviews was only
12 months. Therefore, we can have little conﬁdence
from the systematic review literature in the prospective
use of CVD risk scores translating into long-term clinical
beneﬁts.
There seems to be a widespread acceptance, including
among several guidelines, of total cardiovascular risk
assessment despite no systematic review evidence for its
effectiveness on long-term patient outcomes: neither the
National Institute of Health and Care Excellence
(NICE)8 or WHO41 currently acknowledge this evidence
gap. However, the 2013 American College of Cardiology
(ACC)/American Heart Association (AHA) Guideline
on the Assessment of Cardiovascular risk acknowledges
that ‘none of the risk assessment tools…have been for-
mally evaluated in randomised controlled trials… with
clinical events as outcomes’.42 NICE does go so far as to
make recommendations for research, but overlooks the
need to evaluate the global CVD risk approach.43
Further, global cardiovascular risk assessment is included
in the Quality and Outcomes Framework in the UK as
an incentive for general practitioners to be compliant
with guidance for primary prevention.44
There is evidence, from studies retrospectively risk
scoring patients, that the absolute reduction in CVD
events from cholesterol-lowering and blood pressure-
lowering treatment is associated with baseline CVD
risk.45 46 It is important to distinguish, however, that
these data do not illustrate that the prospective use of
global CVD risk assessment improves patient outcomes,
but suggest that targeting high-risk patients is an efﬁ-
cient way to allocate resources to reduce CVD events.
Nor do studies of calibration and discrimination imply
effectiveness.
We speculate the paucity of data may partly be
explained by the assumption that accuracy of risk scores
is a proxy for effectiveness, therefore undermining
rationale for further study. While mechanical prediction,
such as the use of global cardiovascular risk assessment,
is generally a superior method of data combination than
clinical judgement;47 it is unknown whether this holds
true for cardiovascular risk. Moreover, clinicians still rely
on clinical judgement to integrate risk scores within the
broader context of the patient—especially for risk
factors that are not included in the risk assessment algo-
rithm—therefore risk stratiﬁcation is not strictly a prac-
tice that can be replaced with mechanical prediction.
The uncertainty around the clinical utility of this prac-
tice has been highlighted by UK general practitioners,
who expressed that broad implementation created con-
siderable confusion, and emphasised the need for sim-
pliﬁcation and for guidance to be updated to reﬂect
how risk scores are actually used.15
Strengths and limitations
Our systematic review of systematic reviews was strength-
ened by its broad inclusion criteria, which reduced the
chance we missed relevant literature and allowed us to
include reviews whose primary objective may not have
been assessing the impact of risk assessment. This
method provides quality appraised systematic reviews
and their primary studies and therefore can help inform
policy and practice, in addition to providing new insight
from rigorous data synthesis from a breadth of sources.
It also highlights trends in the systematic review litera-
ture. While there was heterogeneity in the risk scores
used, the exact nature of the interventions, comparisons,
follow-up time and patient demographics, we feel that
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such heterogeneity approximates the reality of clinical
practice. The results therefore provide a good approxi-
mation of impact.
While we believe we have taken steps to ensure an
exhaustive search, it is possible some systematic reviews
were missed. Our post hoc analysis of primary studies
reported by included systematic review should be inter-
preted with caution. Its purpose is to better appraise
and synthesise the primary studies which are already
available in the systematic review literature, and there-
fore it does not represent the conclusions from a system-
atic review of individual primary studies, and it is
possible that further primary studies exist. Given that
these data were not appraised and synthesised to a high
standard in the included systematic reviews, we felt it
necessary to do so. There are likely further primary
studies that can add to our meta-analysis, and high-
quality systematic reviews should be conducted and
these analyses should be updated. We were unable to
perform sensitivity analyses due to a paucity of data. We
did not contact authors of primary studies, which may
have allowed us to adjust unadjusted study results which
we were forced to report narratively. However, as these
studies were reported in systematic reviews, some of
which contacted study authors, we believe the likelihood
of further data becoming available to be minimal, and
the ﬁndings of these studies did not contradict our
overall ﬁndings of the meta-analyses. In addition, we did
not assess publication bias and reporting bias, not least
because of the paucity of evidence, which may lead to
overestimations of the effective sizes. We imputed the SE
of one study,48 which may underestimate heterogeneity;
however sensitivity analysis revealed only a 2% absolute
increase in I2 for the overall effect estimate when this
study was excluded. The current evidence base is limited
in that all patients were from high-income countries,
many were hypertensive and most interventions used a
Framingham-derived risk score.
Implications for research and practice
The ﬁndings of our post hoc meta-analyses should be
interpreted for practice with caution given the paucity of
evidence and its low quality. Policymakers worldwide
should take care when implementing global cardiovascu-
lar risk approaches, especially in an era where prevention
efforts are expanding worldwide, as there was no system-
atic review evidence to suggest that the prospective use of
global cardiovascular risk assessment in clinical practice
reduces CVD events. Although the most recent systematic
review was published in 2015, its literature search was con-
ducted in 2013. Researchers should therefore update and
improve the quality of systematic reviews and focus on
CVD-related morbidity and mortality and other hard
patient outcomes. In some jurisdictions, such as many
low-income and middle-income countries, high-quality
primary studies may be needed and these should be
done before the widespread implementation of CVD risk
scoring or, if not possible, in concert.
CONCLUSION
There is currently no evidence from systematic reviews
that the prospective use of global cardiovascular risk
assessment translates to reductions in CVD events.
Systematic reviews, which were generally of poor quality,
have consistently reported uncertainty about the impact
of this practice on meaningful patient outcomes. These
reviews found no studies reporting CVD-related morbid-
ity or mortality, and the reductions in SBP, cholesterol
and smoking may not be clinically signiﬁcant given their
small effect size and short duration. Despite the wide-
spread popularity of global cardiovascular risk assess-
ment, resources need to be directed in the ﬁrst instance
to conduct high-quality systematic reviews, and further
RCTs powered to measure CVD-related morbidity and
mortality may be needed.
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